Patient case (clinical description): A 41-year-old woman comes to the dermatology clinic complaining of facial redness, especially on her forehead and cheeks. She noticed that the redness gets worse in the summer and after sun exposure. She is otherwise healthy. On physical examination, she has multiple papules and pustules present on her forehead, cheeks, and nose on a background of erythema and telangiectasias. There are no other lesions or nodules. The patient is married and has 2 children who are 5 and 9 years old. She has IUD and doesn't wish to have more kids. She does not smoke or drink alcohol. Her vital signs are normal, and BMI is 21.

Patient's own account: I'm 41, married with 2 lovely kids who are 5 and 9 years old. I have an IUD and I don't want to have more kids. I don't smoke or drink alcohol. I had to go to the dermatology clinic because I had terrible redness on my face, especially on my forehead and cheeks. It got worse in the summer and after being under the sun. I'm usually healthy. They conducted a physical exam and they found several lesions and pustules on my forehead, cheeks and nose and they also found some signs of erythema and telangiectasia. My vitals were normal, and my BMI is 21.

Clinical trial: A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Eligibility criteria:
Inclusion Criteria:

          -  Moderate to severe erythematotelangiectatic rosacea with moderate to severe erythema
             of facial lesion

          -  Generally healthy excluding rosacea

          -  Presence of telangiectasia

          -  Five or less facial inflammatory lesions

          -  Able to restrict diet in order to avoid foods/drinks (including alcohol) that are
             known to exacerbate the signs/symptoms of rosacea

          -  Females of childbearing potential must have negative serum pregnancy test and agree to
             use one form of contraception

        Exclusion Criteria:

          -  Diagnosis of skin disorders, including psoriasis, acne vulgaris, perioral dermatitis
             or atopic dermatitis that would interfere with the clinical evaluations of rosacea

          -  Using and unable to discontinue use of phosphodiesterase (PDE) 4 inhibitors,
             theophylline, niacin greater than 500 mg/day

          -  Known or suspected excessive alcohol intake

          -  Sensitivity to tetracyclines

          -  Ocular rosacea and/or blepharitis/meibomianitis

          -  Pregnant or breastfeeding

          -  Perimenopausal and has symptoms that cause flushing that may affect rosacea

          -  Initiated hormonal method of birth contraception within 4 months of baseline,
             discontinues use during the course of the study, or changes hormonal method within 4
             months

          -  Active mycobacterial infection of any species within 3 years

          -  History of mycobacterium tuberculosis infection

          -  History of recurrent bacterial infection

          -  Congenital or acquired immunodeficiency common variable immunodeficiency (CVID),
             Hepatitis B surface antigen positive or Hepatitis B core antibody positive

          -  Human immunodeficiency virus (HIV) infection

          -  Positive for hepatitis C antibodies

          -  Malignancy or has had a history of malignancy greater than 3 years prior

          -  Will continue to use any of the following treatments during the study: Systemic
             retinoids, therapeutic vitamin A supplements of greater than 10,000 units/day,
             systemic steroids, systemic antibiotics known to have an impact on the severity of
             facial rosacea, systemic treatment for acne, topical steroids, topical retinoids,
             topical acne treatments including prescription and over-the-counter (OTC)
             preparations, topical anti-inflammatory agents, topical antibiotics, topical imidazole
             antimycotics, cryodestruction or chemodestruction, dermabrasion, photodynamic therapy,
             acne surgery, intralesional steroids, X-ray therapy, pulse-dye laser, intense pulse
             light, astringents, abrasives, benzoyl peroxide products, sulfur containing washes,
             eye washes, Beta blockers, vasodilators, vasoconstrictors and/or chronic use (>14
             days) of topical or systemic anti-inflammatory agents
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment